BioSpace News Archive

Innovent Biologics, Inc. and IASO Biotherapeutics jointly announced that the China National Medical Products Administration has formally accepted the New Drug Application for Equecabtagene Autoleucel, a fully human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.

Akeso, Inc. released clinical details in poster discussion featuring a phase II study from Ivonescimab in combination with chemotherapy for advanced non-small cell lung cancer at 2022 ASCO Annual Meeting.

Akeso, Inc. released updated results of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment of recurrent/metastatic cervical cancer.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive head and neck cancer patients.

Agendia, Inc. announced it will present seven posters derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study at the American Society of Clinical Oncology Annual Meeting 2022.

Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions.

eFFECTOR Therapeutics, Inc. reported positive interim results of the company’s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression of multiple oncogenic drivers and demonstrated initial signals of clinical activity.

Innovent Biologics, Inc. presented the preliminary data of IBI351 from dose escalation portion of a phase I clinical trial at the 2022 American Society of Clinical Oncology Annual Meeting.

Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that ENHERTU® demonstrated superior and clinically meaningful progression-free survival and overall survival in previously treated patients with HER2-low 1+ or IHC 2+/in-situ hybridization -negative) unresectable and/or metastatic breast cancer with hormone receptor positive or HR-negative disease versus standard of care physician’s choice of chemotherapy.

Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference of 7.9%,1 making it the first and only 14-day continuous glucose monitoring system to achieve a sub-8% overall MARD.